LAVAL, QC, Sept. 19 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that James R. Howard-Tripp, Chief Executive Officer of the Company
will present at the 2007 UBS Global Life Sciences Conference in New York, on
Wednesday, September 26, 2007 at 9:00 a.m. ET and the CIBC 6th Annual Eastern
Institutional Investor Conference in Mont Tremblant, Quebec on Thursday,
September 27, 2007 at 11:10 a.m. ET.
Interested parties may access the live webcasts for each of these
presentations by visiting the "Events" section of the homepage of the
Company's website at www.labopharm.com. Please connect at least 15 minutes
prior to the presentation to ensure adequate time for any software download
that may be required to join the webcast. An audio archive of the presentation
will be available for 30 days.
About the UBS Global Life Sciences Conference
The annual UBS Global Life Sciences Conference is among the largest
health care investor conferences in the world. Senior executives from the
leading biotechnology, medical device manufacturing, pharmaceuticals and
specialty pharmaceutical companies will provide their insight and outlook on
the global life sciences industry.
About the CIBC Annual Eastern Institutional Investor Conference
The CIBC World Markets 6th Annual Eastern Institutional Investor
Conference, to be held this year in Mont Tremblant, Quebec, will include
presentations by senior executives from more than 50 prominent Canadian and
U.S. companies. Presentation tracts will include diversified industries,
financial institutions & insurance, technology, media & telecom, health and
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company has a robust
pipeline of follow-on products in both pre-clinical and clinical development.
Labopharm's vision is to become a fully integrated, international, specialty
pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process and the
commercialization of the Company's products thereafter, if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm: Mark A. D'Souza, Chief Financial
Officer, (450) 686-0207; At The Equicom Group: Jason Hogan, Media and Investor
Relations, (416) 815-0700, firstname.lastname@example.org; French: Eric Bouchard,
(514) 844-7997, email@example.com